Grants and Contracts Details
Description
ABSTRACT
A RANDOMIZED TRIAL OF LOW-DOSE BEVACIZUMAB VERSUS LASER FOR TYPE 1 RETINOPATHY OF
PREMATURITY
This randomized clinical trial will compare retinal outcomes with low-dose intravitreous bevacizumab
(0.063 mg) versus laser photocoagulation as treatment for infants with type 1 retinopathy of
prematurity (ROP).
The study also will assess neurodevelopment, refractive error, visual acuity, and peripheral visual fields.
The primary objective is to determine if infants with type 1 ROP treated with intravitreous bevacizumab
have retinal treatment success rates that are noninferior to that of infants treated with laser
photocoagulation.
Secondary objectives are to compare the number of re-treatments, extent of retinal vascularization,
refractive error, visual acuity, visual fields, neurodevelopment, and systemic morbidities between
treatment groups
Status | Finished |
---|---|
Effective start/end date | 11/1/21 → 7/19/24 |
Funding
- Jaeb Center for Health Research Foundation Incorporated: $7,649.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.